Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yissum Introduces a Pioneering Vaccine Against CME

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine.

Canine monocytic ehrlichiosis (CME) is a major, potentially fatal, tick-borne dog disease prevalent worldwide.

No commercial vaccine for the disease is currently available and tick control is the main preventive measure against the disease.

Now, Yissum Research and Development Company of the Hebrew University of Jerusalem, introduces a vaccine against CME, which was developed by Professors Shimon Harrus and Gad Baneth, from the Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences at the Hebrew University of Jerusalem.

The vaccine has proven effective in an experimental study in dogs, which was recently published in the prestigious journal Vaccine.

Profs. Harrus and Baneth developed the vaccine from a proprietary attenuated strain of Ehrlichia canis, the bacteria that causes CME. The efficiency of the attenuated strain as a vaccine was assessed on 12 dogs, which were divided into three groups.

Four dogs were inoculated (vaccinated) with the attenuated Ehrlichia strain twice, four dogs only once and the last group of four dogs served as the control group.

The vaccinated dogs showed no clinical signs after the inoculation, suggesting that the novel vaccine is safe for use and does not induce adverse effects.

When the dogs were infected with a virulent Ehrlichia field strain, the control dogs all developed a severe disease, whereas only three of the eight vaccinated dogs presented mild transient fever and the rest remained healthy.

"Canine monocytic ehrlichiosis is a serious dog disease that can lead to death. Current treatment includes supportive care, and a harsh and lengthy antibiotic treatment, which may not be effective in chronic infections. The vaccine developed by Profs. Harrus and Baneth is the first vaccine to prove effective against this disease," said Yaacov Michlin, CEO of Yissum.

Michlin continued, "The current lack of vaccine for CME, the growing awareness of the market and the growing market needs make this invention particularly attractive, and Yissum is currently looking for commercial partners for further development and commercialization purposes."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
Study Reveals New Method to Develop More Efficient Drugs
A new study suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!